Synthetic peptide vaccines and the search for neutralization B cell epitopes

Open Vaccine Journal

Volumn 2, Issue , 2009, Pages 33-44

  Van Regenmortel, M H V ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Antigenicity; Epitope prediction; HIV; Immunogenicity; Mimotopes; Monoclonal antibodies; Peptide based vaccines; Synthetic peptides

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANTIGEN; EPITOPE; MIMOTOPE; MONOCLONAL ANTIBODY; NEOTOPE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; PROTEIN; SYNTHETIC PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGENICITY; B LYMPHOCYTE; BORRELIA BURGDORFERI; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CROSS REACTION; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LYME DISEASE; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEM ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 74449086766     PISSN: None     EISSN: 18750354     Source Type: Journal    
DOI: 10.2174/1875035400902010033     Document Type: Conference Paper

References (110)

1. Van Regenmortel, M.H.V.; Muller, S. In Synthetic Peptides as Antigens; Van Regenmortel, M.H.V.; Muller, S., Eds.; Elsevier: Amsterdam, 1999, pp. 281-317.
2. Arnon, R. Synthetic Vaccines; CRC Press: Boca Raton, FL, 1987.
3. Nicholson, B.H. Synthetic Vaccines; Blackwell Scientific Publishers: Oxford, 1994.
4. Arnon, R.; Ben Yedidia, T. Old and new vaccine approaches. Int. Immunopharmacol., 2003, 3(8), 1195-1204.
5. Sundaram, R.; Dakappagari, N.K.; Kaumaya, P. Synthetic peptides as cancer vaccines. Biopolymers, 2002, 66(3), 200-216.
6. Hans, D.; Young, P.R.; Fairlie, D.P. Current status of short synthetic peptides as vaccines. Med. Chem., 2006, 2(6), 627-646. (Pubitemid 44741618)
7. Watkins, D.I.; Burton, D.R.; Kallas, E.G.; Moore, J.P.; Koff, W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med., 2008, 14(6), 617-621.
8. Atassi, M.Z.; Smith, J.A. A proposal for the nomenclature of antigenic sites in peptides and proteins. Immunochemistry, 1978, 15(8), 609-610.
9. Van Regenmortel, M.H.V. In Synthetic Peptides as Antigens; Van Regenmortel, M.H.V.; Muller, S., Eds.; Elsevier: Amsterdam, 1999, pp. 1-78.
10. Li, H.; Dunn, J.J.; Luft, B.J.; Lawson, C.L. Crystal structure of Lyme disease antigen outer surface protein A complexed with an Fab. Proc. Natl. Acad. Sci. USA, 1997, 94(8), 3584-3589.
11. Van Regenmortel, M.H.V. Structural and functional approaches to the study of protein antigenicity. Immunol. Today, 1989, 10(8), 266-272.
12. Zhang, Q.; Wang, P.; Kim, Y.; Haste-Andersen, P.; Beaver, J.; Bourne, P.E.; Bui, H-H.; Buus, S.; Frankild, S.; Greenbaum, J.; Lund, O.; Lundegaard, C.; Nielsen, M.; Ponomarenko, J.; Sette, A.; Zhu, Z.; Peters, B. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res., 2008, 36, (web server issue) w513-w518.
13. Roberts, V.A.; Getzoff, E.D.; Tainer, J.A. In Structure of Antigens; Van Regenmortel, M.H.V., Ed.; CRC Press: Boca Raton, FL, 1993, Vol. 2, pp. 31-53.
14. Laver, W.G.; Air, G.M.; Webster, R.G.; Smith-Gill, S.J. Epitopes on protein antigens: misconceptions and realities. Cell, 1990, 61(4), 553-556. (Pubitemid 20169012)
15. Van Regenmortel, M.H.V. Immunoinformatics may lead to a reappraisal of the nature of the B cell epitopes and of the feasibility of synthetic peptide vaccines. J. Mol. Recognit., 2006, 19(3), 183-187.
16. Van Regenmortel, M.H.V. Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology. Vaccine, 1999, 18, 216-221.
17. Zwick, M.B. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS, 2005, 19(16), 1725-1737.
18. Montero, M.; van Houten, N.E.; Wang, X.; Scott, J.K. The membrane-proximal external region of the human immunodeficiency virus Type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev., 2008, 72(1), 54-84.
19. Ho, J.; Uger, R.A.; Zwick, M.B.; Luscher, M.A.; Barber, B.H.; MacDonald, K.S. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine, 2005, 23(13), 1559-1573.
20. Joyce, J.G.; Hurni, W.M.; Bogusky, M.J.; Garsky, M.; Liang, X.; Citron, M.P.; Danzeisen, R.C.; Miller, M.D.; Shiver, J.W.; Keller, P.M. Enhancement of alpha -Helicity in the HIV-1 Inhibitory Peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. J. Biol. Chem., 2002, 277(48), 45811-45820.
21. Zwick, M.B.; Jensen, R.; Church, S.; Wang, M.; Stiegler, G.; Kunert, R.; Katinger, H.; Burton, D.R. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol., 2005, 79(2), 1252-1261.
22. Ofek, G.; Tang, M.; Sambor, A.; Katinger, H.; Mascola, J.R.; Wyatt, R.; Kwong, P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol., 2005, 78(19), 10724-10737.
23. Neurath, A.R.; Strick, N.; Lin, K.; Jiang, S. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res. Hum. Retroviruses, 1995, 11(6), 687-696.
24. Van Regenmortel, M.H.V. The rational design of biological complexity: a deceptive metaphor. Proteomics, 2007, 7(6), 965-975.
25. Van Regenmortel, M.H.V. Transcending the structuralist paradigm in immunology - affinity and biological activity rather than purely structural considerations should guide the design of synthetic peptide epitopes. Biomed. Pept. Protein Nucl. Acids, 1995, 1(3), 109-116.
26. Van Regenmortel, M.H.V.; Muller, S. Synthetic Peptides as Antigens; Elsevier: Amsterdam, 1999.
27. Saphire, E.O.; Montero, M.; Menendez, A.; van Houten, N.E.; Irving, M.B.; Pantophlet, R.; Zwick, MB.; Parren, P.W.H.I.; Burton, D.R.; Scott, J.K.; Wilson, I.A. Crystal structure of a broadly neutralizing anti-HIV-1 antibody in complex with a peptide: mechanism of gp120 cross-reactivity. J. Mol. Biol., 2007, 369(3), 696-709.
28. Van Regenmortel, M.H.V. Plant virus serology. Adv. Virus Res., 1966, 12, 207-271.
29. Van Regenmortel, M.H.V. The conformational specificity of viral epitopes. FEMS Microbiol. Lett., 1992, 100(1-3), 483-488.
30. Boeyé, A.; Rombaut, B. The proteins of poliovirus. Prog. Med. Virol., 1992, 62, 139-166.
31. Neurath, A.R.; Rubin, B.A. Viral Structural Components as Immunogens of Prophylactic Value. Monographs in Virology. Karger: Basel, 1971.
32. Bothner, B.; Dong, X.F.; Bibbs, L.; Johnson, J.E.; Suizdak, G. Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry. J. Biol. Chem., 1998, 273(2), 673-676.
33. Zolla-Pazner, S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol., 2004, 4(3), 199-210. (Pubitemid 38339086)
34. Zwick, M.B.; Burton, D.R. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr. HIV Res., 2007, 5(6), 608-624. (Pubitemid 351210995)
35. Geysen, H.M.; Rodda, S.J.; Mason, T.J. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol. Immunol., 1986, 23(7), 709-715.
36. Delmastro, P.; Meola, A.; Monaci, P.; Cortese, R.; Galfre, G. Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Vaccine, 1997, 15(11), 1276-1285. (Pubitemid 27372112)
37. Tropsha, J; S.; Kizer, J.S.; Chaiken, I.M. Making sense from antisense: a review of experimental data and developing ideas on sense-antisense peptide recognition. J. Mol. Recognit., 1992, 5(2), 43-54.
38. Van Oss, C.J. Hydrophobic, hydrophilic and other interactions in epitope-paratope binding. Mol. Immunol., 1995, 32(3), 199-211.
39. Boquet, D.; Déry, O.; Forbert, Y.; Grassi, J.; Couraud, J.Y. Is hydropathic complementarity involved in antigen-antibody binding? Mol. Immunol., 1995, 32(4), 303-308.
40. Hanin, V.; Déry, O.; Boquet, D.; Sagot, M-A.; Cremoin, C.; Couraud, J.Y.; Grassi, J. Importance of hydropathic complementarity for the binding of the neuropeptide substance P to a monoclonal antibody: equilibrium and kinetic studies. Mol. Immunol., 1997, 34(12-13), 829-838. (Pubitemid 28086164)
41. Van Regenmortel, M.H.V. Antigenicity and immunogenicity of synthetic peptides. Biologicals, 2001, 29(3-4), 209-213.
42. Meloen, R.H.; Puyk, W.C.; Sloostra, J.W. Mimotopes: realization of an unlikely concept. J. Mol. Recognit., 2000, 13(6), 352-359.
43. Larralde, OG.; Martinez, R.; Camacho, F.; Amin, N.; Aguilar, A.; Talavera, A.; Stott, D.L.; Perez, E.M. Identification of hepatitis A virus mimotopes by phage display, antigenicity and immunogenicity. J. Virol. Methods, 2007, 140(1-2), 49-58.
44. Van Regenmortel, M.H.V. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites. J. Immunol. Methods, 1998, 216(1-2), 37-48.
45. James, L.C.; Roversi, P.; Tawfik, D.S. Antibody multi-specificity mediated by conformational diversity. Science, 2003, 299(5611), 1362-1367.
46. Demchenko, A.P. Recognition between flexible protein molecules: induced and assisted folding. J. Mol. Recognit., 2001, 14(1), 42-61.
47. Ma, B.; Shatsky, M.; Wolfson, H.J.; Nussinov, R. Multiple diverse ligands binding at a single protein site: A matter of pre-existing populations. Protein Sci., 2002, 11(2), 184-197. (Pubitemid 34075781)
48. Getzoff, E.D.; Tainer, J.A.; Lerner, R.A.; Geysen, H.M. The chemistry and mechanism of antibody binding to protein antigens. Adv. Immunol., 1988, 43, 1-98. (Pubitemid 19015628)
49. Benjamin, D.C.; Berzofsky, J.A.; East, I.J.; Gurd, F.R.N.; Hannum, C.; Leach, S.J.; Margoliash, E.; Michael, J.G.; Miller, A.; Prager, E.M.; Reichlin, M.; Sercaz, E.E.; Smith-Gill, S.J.; Todd, PE.; Wilson, A.C. The antigenic structure of proteins: A reappraisal. Ann. Rev. Immunol., 1984, 2, 67-101.
50. Rubinstein, N.D.; Mayrose, I.; Halperin, D.; Yekutieli, D.; Gershoni, J.M.; Pupko, T. Computational characterization of B-cell epitopes. Mol. Immunol., 2008, 45(12), 3477-3489.
51. Tilley, S.A.; Honnen, W.J.; Racho, M.E.; Chou, T.C.; Pinter, A. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4 binding site of gp120. AIDS Res. Hum. Retroviruses, 1992, 8(4), 461-467.
52. Laal, S.; Burda, S.; Gorny, M.K.; Karwowska, S.; Buchbinder, A.; Zolla-Pazner, S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J. Virol., 1994, 68(6), 4001-4008. (Pubitemid 24177426)
53. Mascola, J.R.; Louder, M.K.; VanCott, T.C.; Sapan, C.V.; Lambert, J.S.; Muenz, L.R.; Bunow, B.; Birx, D.L.; Robb, M.L. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virol., 1997, 71(10), 7198-7206.
54. Zeder-Lutz, G.; Hoebeke, J.; Van Regenmortel, M.H.V. Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies. Eur. J. Biochem., 2001, 268(10), 2856-2866.
55. Zwick, M.B.; Wang, M.; Poignard, P.; Stiegler, G.; Katinger, H.; Burton, D.R.; Parren, W.H.I. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol., 2001, 75(24), 12198-12208. (Pubitemid 33115893)
56. Poon, B.; Safrit, J.T.; McClure, H.; Kitchen, C.; Hsu, J.F.; Gudeman, V.; Petropoulos, C.; Wrin, T.; Chen, I.S.Y.; Grovit-Ferbas, K. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J. Virol., 2005, 79 (8), 4927-4935. (Pubitemid 40464243)
57. Poon, B.; Hsu, J.F.; Gudeman, V.; Chen, I.S.Y.; Grovit-Ferbas, K. Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses. J. Virol., 2005, 79(16), 10210-10217.
58. Crooks, E.T.; Moore, P.L.; Franti, M.; Cayanan, C.S.; Zhu, P.; Jiang, P.; de Vries, R.P.; Wiley, C.; Zharkikh, I.; Schülke, N.; Roux, K.H.; Montefiori, D.C.; Burton, D.R.; Binley, J.M. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology, 2007, 366(2), 245-262. (Pubitemid 47393683)
59. Lescar, J.; Pelligrini, M.; Souchon, H.; Tello, D.; Poljak, R.J.; Peterson, N.; Greene, M.; Alzari, M. Crystal structure of a crossreaction complex between Fab F9.13.7 and guinea fowl lysozyme. J. Biol. Chem., 1995, 270(30), 18067-18076.
60. Schroer, J.A.; Bender, T.; Feldmann, T.; Kim, K.J. Mapping epitopes on the insulin molecule using monoclonal antibodies. Eur. J. Immunol., 1983, 13(9), 693-700.
61. Edwards, B.M.; Barash, S.C.; Main, S.H.; Choi, G.H.; Minter, R.; Ullrich, S.; Williams, E.; Du Fou, L.; Wilton, J.; Albert, V.R.; Ruben, S.M.; Vaughan, T.J. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J. Mol. Biol., 2003, 334(1), 103-118.
62. Brunel, F.M.; Zwick, M.B.; Cardoso, R.M.F.; Nelson, J.D.; Wilson, I.A.; Burton, D.R.; Dawson, P.E. Structure-function analysis of the epitope for 4E10, a humanimmunodeficiency virus type 1 (HIV-1) broadly neutralizing antibody. J. Virol., 2006, 80(4), 1680-1687.
63. Nelson, J.D.; Brunel, F.M.; Jensen, R.; Crooks, E.T.; Cardoso, R.M.F.; Wang, M.; Hessel, A.; Wilson, I.A.; Zwick, M.B. An affinity- enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol., 2007, 81(8), 4033-4043.
64. Javaherian, K.; Langlois, A.J.; McDanal, C.; Ross, K.L.; Eckler, L.I.; Jellis, CL.; Profy, A.T.; Rusche, J.R.; Bolognesi, D.P.; Putney, S.D.; Matthews, T.J. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. USA, 1989, 86(17), 6768-6772. (Pubitemid 19236342)
65. Spear, G.R.; Takefman, D.M.; Sharpe, S.; Ghassemi, M.; Zolla- Pazner, S. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology, 1994, 204(2), 609-615.
66. VanCott, T.C.; Polonis, V.R.; Loomis, L.D.; Michael, N.L.; Nara, P.L.; Birx, D.L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses, 1995, 11(11), 1379-1391.
67. Beddows, S.A.; Louisirirotchanakul, S.; Cheingsong-Popov, R.; Easterbrook, P.J.; Simmonds, P.; Weber, J.N. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J. Gen. Virol., 1998, 79(1), 77-82. (Pubitemid 28039303)
68. Spenlehauer, C.; Saragosti, S.; Fleury, H.J.; Kirn, A.; Aubertin, A.M.; Moog, C. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus Tcell- line-adapted strains of human immunodeficiency virus type 1. J. Virol., 1998, 72(12), 9855-9864. (Pubitemid 28520851)
69. Kayman, S.C.; Wu, Z.; Revesz, K.; Chen, H.; Kopelman, R.; Pinter, A. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J. Virol., 1994, 68(1), 400-410. (Pubitemid 24974644)
70. Gorny, M.K.; Williams, C.; Volsky, B.; Revesz, K.; Cohen, S.; Polonis, V.R.; Honnen, W.J.; Kayman, S.C.; Krachmarov, C.; Pinter, A.; Zolla-Pazner, S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol., 2002, 76(18), 9035-9045. (Pubitemid 34919862)
71. Richalet-Secordel, P.; Zeder-Lutz, G.; Plaue, S.; Sommermeyer- Leroux, G.; Van Regenmortel, M.H.V. Cross-reactivity of monoclonal antibodies to a chimeric V3 peptide of HIV-1 with peptide analogues studied by biosensor technology and ELISA. J. Immunol. Methods., 1994, 176(2), 221-234. (Pubitemid 24369218)
72. Rini, J.M.; Schulze-Gahmen, U.; Wilson, I.A. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science, 1992, 255(5047), 959-965.
73. Churchill, M.E.A.; Stura, E.A.; Pinilla, C.; Appel, J.R.; Houghten, R.A.; Kono, D.H.; Balderas, R.S.; Fieser, G.G.; Schulze-Gahmen, U.; Wilson, I.A. Crystal structure of a peptide complex of antiinfluenza peptide antibody Fab 26/9. Comparison of two different antibodies bound to the same peptide antigen. J. Mol. Biol., 1994, 241(4), 534-556. (Pubitemid 124002172)
74. Wilson, I.A.; Stanfield, R.L. Antibody-antigen interactions: new structures and new conformational changes. Curr. Opin. Struct. Biol., 1994, 4(6), 857-867.
75. Berger, C.; Weber-Bornhauser, S.; Eggenberger, H.; Hanes, J.; Pluckthun, A.; Bosshard, H.R. Antigen recognition by conformational selection. FEBS Lett., 1999, 450(1-2), 149-153.
76. Bosshard, H.R. Molecular recognition by induced fit: how fit is the concept? News Physiol. Sci., 2001, 16(8), 171-173.
77. Goh, C.S.; Milburn, D.; Gerstein, M. Conformational changes associated with protein-protein interactions. Curr. Opin. Struct. Biol., 2004, 14(1), 104-109. (Pubitemid 38258244)
78. Stanfield, R.L.; Gorny, M.K.; Zolla-Pazner, S.; Wilson, I.A. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol., 2006, 80(12), 6093-6105.
79. Muller, S. In Synthetic Peptides as Antigens; Van Regenmortel, M.H.V.; Muller, S., Eds.; Elsevier: Amsterdam, 1999, pp. 133-177.
80. Benito, A.; Van Regenmortel, M.H.V. Biosensor characterization of antigenic site A of foot-and-mouth disease virus presented in different vector systems. FEMS Immunol. Med. Microbiol., 1998, 21(2), 101-115.
81. Chakraborty, K.; Durani, V.; Miranda, E.R.; Citron, M.; Liang, X.; Schleif, W.; Joyce, J.G.; Varadarajan, R. Design of immunogens that present the crown of the HIV-IV3 loop in a conformation competent to generate 447-52 D-like antibodies. Biochem. J., 2006, 399, 483-491. (Pubitemid 44672639)
82. Rybicki, E.P. Plant-produced vaccines: promise and reality. Drug Discov.Today, 2009, 14(1-2), 16-24.
83. Gorny, M.K.; Xu, J-Y.; Karwowska, S.; Buchbinder, A.; Zolla- Pazner, S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol., 1993, 150(2), 635-643. (Pubitemid 23133641)
84. Gorny, M.K.; Revesz, K.; Williams, C.; Volsky, B.; Louder, M.K.; Anyangwe, C.A.; Krachmarov, C.; Kayman, S.C.; Pinter, A.; Nadas, A.; Nyambi, P.N.; Mascola, J.R.; Zolla-Pazner, S. The V3 Loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J. Virol., 2004, 78(5), 2394-2404. (Pubitemid 38228932)
85. Rosen, O.; Chill, J.; Sharon, M.; Kessler, N.; Mester, B.; Zolla- Pazner, S.; Anglister, J. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry, 2005, 44(19), 7250-7258. (Pubitemid 40656668)
86. Leinikki, P.; Lehtinen, M.; Hyoty, H.; Parkkonen, P.; Kantanen, M.L.; Hakulinen, J. Synthetic peptides as diagnostic tools in virology. Adv. Virus Res., 1993, 42, 149-186.
87. Gomara, M.J.; Haro, I. Synthetic peptides for the immunodiagnosis of human diseases. Curr. Med. Chem., 2007, 14(5), 531-546. (Pubitemid 46477726)
88. Pellequer, J.L.; Westhof, E.; Van Regenmortel, M.H.V. Predicting location of continuous epitopes in proteins from their primary structures. Methods. Enzymol., 1991, 203, 176-201.
89. nd., Gu, J.; Bourne, P.E., Eds.; John Wiley: Hoboken, N.J. 2009, pp. 849-879.
90. Pellequer, J.L.; Westhof, E.; Van Regenmortel, M.H.V. Correlation between the location of antigenic sites and the prediction of turns in proteins. Immunol. Lett., 1993, 36(1), 83-99.
91. Blythe, M.J.; Flower, D.R. Benchmarking B cell epitope prediction: Underperformance of existing methods. Protein Sci., 2005, 14(1), 246-248.
92. Greenbaum, J.A.; Andersen, P.H.; Blythe, M.; Bui, H.H.; Cachau, R.E.; Crowe, J.; Davies, M.; Kolaskar, A.S.; Lund, O.; Morrison, S.; Mumey, B.; Ofran, Y.; Pellequer, J.L.; Pinilla, C.; Ponomarenko, J.V.; Raghava, G.P.; Van Regenmortel, M.H.V.; Roggen, E.L.; Sette, A.; Schlessinger, A.; Sollner, J.; Zand, M.; Peters, B. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J. Mol. Recognit., 2007, 20(2), 75-82. (Pubitemid 46761248)
93. Hopp, T.P. Retrospective: 12 years of antigenic determinant predictions, and more. Pept. Res., 1993, 6(4), 183-190.
94. Van Regenmortel, M.H.V.; Pellequer, J.L. Predicting antigenic determinants in proteins: looking for unidimensional solutions to a three-dimensional problem? Pept. Res., 1994, 7(4), 224-228.
95. Kulkarni-Kale, U.; Bhosle, S.; Kolaskar, A.S. CEP: a conformational epitope prediction server. Nucl. Acids Res. 2005, 33 (Web server issue), W168-W171.
96. Haste A.P.; Nielsen, M.; Lund, O. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci., 2006, 15(11), 2558-2567. (Pubitemid 44771693)
97. Moreau, V.; Granier, C.; Villard, S.; Laune, D.; Molina, F. Discontinuous epitope prediction based on mimotope analysis. Bioinformatics, 2006, 22(9), 1088-1095.
98. Moreau, V.; Fleury, C.; Piquer, D.; Nguyen, C.; Novali, N.; Villard, S.; Laune, D.; Granier, C.; Molina, F. PEPOP: computational design of immunogenic peptides. BMC Bioinform., 2008, 9, 71.
99. Bublil, E.M.; Freund, N.T.; Mayrose, I.; Penn, O.; Roitburd- Berman, A.; Rubinstein, N.D.; Pupko, T.; Gershoni, J.M. Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Proteins, 2007, 68(1), 294-304.
100. Sweredoski, M.J.; Baldi, P. PEPITO: improved discontinuous Bcell epitope prediction using multiple distance thresholds and half sphere exposure. Bioinformatics, 2008, 24(12), 1459-1460.
101. Oomen, C.J.; Hoogerhout, P.; Bonvin, A.M.; Kuipers, B.; Brugghe, H.; Timmermans, H.; Haseley, S.R.; van Alphen, L.; Gros, P. Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations. J. Mol. Biol., 2003, 328(5), 1083-1089. (Pubitemid 36506875)
102. Enshell-Seijffers, D.; Denisov, D.; Groisman, B.; Smelyanski, L.; Meyuhas, R.; Gross, G.; Denisova, G.; Gershoni, J.M. The mapping and reconstitution of a conformational discontinuous Bcell epitope of HIV-1. J. Mol. Biol., 2003, 334(1), 87-101.
103. Villen, J.; de Oliveira, E.; Nunez, J.I.; Molina, N.; Sobrino, F.F.; Andreu, D. Towards a multi-site synthetic vaccine to foot-andmouth disease: addition of discontinuous site peptide mimic increases the neutralization response in immunized animals. Vaccine, 2004, 22(27-28), 3523-3529. (Pubitemid 39099629)
104. Dakappagari, N.K.; Lute, K.D.; Rawale, S.; Steele, J.T.; Allen, S.D.; Phillips, G.; Reilly, R.T.; Kaumaya, P.T. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J. Biol. Chem., 2005, 280(1), 54-63.
105. Misumi, S.; Nakayama, D.; Kusaba, M.; Iiboshi, T.; Mukai, R.; Tachibana, K.; Nakasone, T.; Umeda, M.; Shibata, H.; Endo, M.; Takamune, N.; Shoji, S. Effects of immunization with CCR5- Based cycloimmunogen on Simian/HIVSF162P3 challenge. J. Immunol., 2006, 176(1), 463-471. (Pubitemid 43023292)
106. Timmerman, P.; Beld, J.; Puijk, W.C.; Meloen, R.H. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. Chembiochem, 2005, 6(5), 821-824.
107. Timmerman, P.; Puijk, W.C.; Meloen, R.H. Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology. J Mol. Recognit., 2007, 20(5), 283-299.
108. DeLano, W.L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol., 2002, 12(1), 14-20.
109. Van Regenmortel, M.H.V. Reductionism and the search for structure-function relationships in antibody molecules. J. Mol. Recognit., 2002, 15(5), 240-247.
110. Van Regenmortel, M.H.V. Reductionism and complexity in molecular biology. EMBO Reports, 2004, 5(11), 1016-1020.